Proteomics International Says Results Validate Blood Test for Diagnosis of Esophageal Cancer, Shares Jump 7%

MT Newswires Live

2025/09/08

Proteomics International Laboratories (ASX:PIQ) said results from a study showed that its PromarkerEso blood test can diagnose the early stages of esophageal adenocarcinoma with high accuracy, according to a Monday Australian bourse filing.

The study analyzed 350 people across two independent cohorts. Cohort A compared 89 healthy controls with esophageal adenocarcinoma samples of known stage, while cohort B compared 40 negative controls with unstaged esophageal adenocarcinoma and Barrett's Esophagus samples.

The blood test showed diagnostic accuracy for all stages of esophageal cancer. The results showed that the severity of disease is significantly correlated with increasing PromarkerEso test scores.

The study was published online ahead of presentation at the annual ISDE World Congress for Esophageal Diseases in Brisbane.

Its shares jumped 7% in early trading on Monday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2565753265"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565753265\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565753265?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 08:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565753265","market":"us","top_or_hot":-1,"title":"Proteomics International Says Results Validate Blood Test for Diagnosis of Esophageal Cancer, Shares Jump 7%","media":"MT Newswires Live","content":"<html><body><p> Proteomics International Laboratories (ASX:PIQ) said results from a study showed that its PromarkerEso blood test can diagnose the early stages of esophageal adenocarcinoma with high accuracy, according to a Monday Australian bourse filing.</p><p>The study analyzed 350 people across two independent cohorts. Cohort A compared 89 healthy controls with esophageal adenocarcinoma samples of known stage, while cohort B compared 40 negative controls with unstaged esophageal adenocarcinoma and Barrett's Esophagus samples.</p><p>The blood test showed diagnostic accuracy for all stages of esophageal cancer. The results showed that the severity of disease is significantly correlated with increasing PromarkerEso test scores.</p><p>The study was published online ahead of presentation at the annual ISDE World Congress for Esophageal Diseases in Brisbane.</p><p>Its shares jumped 7% in early trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Proteomics International Says Results Validate Blood Test for Diagnosis of Esophageal Cancer, Shares Jump 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProteomics International Says Results Validate Blood Test for Diagnosis of Esophageal Cancer, Shares Jump 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-08 08:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Proteomics International Laboratories (ASX:PIQ) said results from a study showed that its PromarkerEso blood test can diagnose the early stages of esophageal adenocarcinoma with high accuracy, according to a Monday Australian bourse filing.</p><p>The study analyzed 350 people across two independent cohorts. Cohort A compared 89 healthy controls with esophageal adenocarcinoma samples of known stage, while cohort B compared 40 negative controls with unstaged esophageal adenocarcinoma and Barrett's Esophagus samples.</p><p>The blood test showed diagnostic accuracy for all stages of esophageal cancer. The results showed that the severity of disease is significantly correlated with increasing PromarkerEso test scores.</p><p>The study was published online ahead of presentation at the annual ISDE World Congress for Esophageal Diseases in Brisbane.</p><p>Its shares jumped 7% in early trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PIQ.AU","symbol_name":"PROTEOMICS INTERNATIONAL LAB","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2565753265","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565753265","pubTimestamp":1757292681,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Proteomics International Laboratories  said results from a study showed that its PromarkerEso blood test can diagnose the early stages of esophageal adenocarcinoma with high accuracy, according to a Monday Australian bourse filing.The study analyzed 350 people across two independent cohorts. Cohort A compared 89 healthy controls with esophageal adenocarcinoma samples of known stage, while cohort B compared 40 negative controls with unstaged esophageal adenocarcinoma and Barrett's Esophagus samples.The blood test showed diagnostic accuracy for all stages of esophageal cancer. The results showed that the severity of disease is significantly correlated with increasing PromarkerEso test scores.The study was published online ahead of presentation at the annual ISDE World Congress for Esophageal Diseases in Brisbane.Its shares jumped 7% in early trading on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PIQ.AU":"PROTEOMICS INTERNATIONAL LAB","BK7508":"医药生物股","BK7048":"生命科学工具和服务"},"translate_title":"Proteomics International表示结果验证了血液测试诊断食道癌的有效性，股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PIQ.AU":0.9},"content_text":"Proteomics International Laboratories (ASX:PIQ) said results from a study showed that its PromarkerEso blood test can diagnose the early stages of esophageal adenocarcinoma with high accuracy, according to a Monday Australian bourse filing.The study analyzed 350 people across two independent cohorts. Cohort A compared 89 healthy controls with esophageal adenocarcinoma samples of known stage, while cohort B compared 40 negative controls with unstaged esophageal adenocarcinoma and Barrett's Esophagus samples.The blood test showed diagnostic accuracy for all stages of esophageal cancer. The results showed that the severity of disease is significantly correlated with increasing PromarkerEso test scores.The study was published online ahead of presentation at the annual ISDE World Congress for Esophageal Diseases in Brisbane.Its shares jumped 7% in early trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}